Panobinostat for adults with severe sickle cell
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early-phase study tests panobinostat, a medicine aimed at reducing sickle-cell problems, in adults with severe disease. It’s mainly looking at safety and whether it can improve blood-related issues that drive pain and complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign written informed consent
- You have confirmed sickle cell with either SS disease or S-beta zero thalassemia
- You cannot tolerate hydroxyurea, do not want it, or it did not work for you
- You have significant sickle-cell complications in the last time periods (pain crises, hospital stays, ulcers, acute chest syndrome, priapism, or stroke)
- No recent crisis: your last pain crisis needing injection-type (parenteral) treatment was more than 2 weeks ago
- Your blood tests and organ function fall in required safe ranges, and your heart rhythm/ECG is acceptable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial uses gene editing to fix your own blood stem cells, so you can stop having severe sickle cell crises. It is for young adults with frequent pain episodes or who need regular blood transfusions.
This trial tests a high-dose medicine to collect stem cells from young adults with sickle cell disease. It aims to prepare for a transplant that could potentially cure the condition.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.